Mitomycin-C Induced Hemolytic Uremic Syndrome: A Case Report and Literature Review

Dou Chen Wu, Jacqueline Ming Liu, Yuh Min Chen, Shuling Yang, Shian Min Liu, Li Tzong Chen, Jacqueline Whang-Peng

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


Hemolytic uremic syndrome spontaneously arises in a few patients with advanced cancer, but it is more commonly related to the use of certain chemotherapeutic agents. Mitomycin-C is, etiologically, the most common causative agent inducing hemolytic uremic syndrome, in a dose dependent manner. We report this syndrome, attributable to mitomycin-C at a cumulative dose of 40 mg/m2, in a gastric cancer patient. A 42-year-old female with stage III gastric cancer underwent radical gastrectomy and was given mitomycin-C at 10 mg/m2 intravenously every four weeks as adjuvant therapy. Hemolytic uremic syndrome was diagnosed three months after the last dose of mitomycin-C administration. The most prominent symptoms included pallor, hypertension and anasarca, with laboratory evidence of microangiopathic hemolytic anemia, azotemia and hyperkalemia. Her disease was progressive, but fortunately stabilized after staphylococcus column A dialysis. Her disease remained in remission for 24 months from the time of diagnosis, and then relapsed in the form of peritoneal carcinomatosis with partial intestinal obstruction.

Original languageEnglish
Pages (from-to)115-118
Number of pages4
JournalJapanese Journal of Clinical Oncology
Issue number2
Publication statusPublished - Dec 1 1997
Externally publishedYes


  • Hemolytic uremic syndrome
  • Mitomycin-C
  • Staphylococcal A column dialysis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Mitomycin-C Induced Hemolytic Uremic Syndrome: A Case Report and Literature Review'. Together they form a unique fingerprint.

Cite this